WallStSmart
PMCB

PharmaCyte Biotech Inc

NASDAQ: PMCB · HEALTHCARE · BIOTECHNOLOGY

$0.79
-3.50% today

Updated 2026-06-05

Market cap
$8.52M
P/E ratio
P/S ratio
12,904.41x
EPS (TTM)
$-0.89
Dividend yield
52W range
$1 – $2
Volume
0.2M

PharmaCyte Biotech Inc (PMCB) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-8.42%
ROA
-6.75%
Debt/equity

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2006$537038.00$-9.38M100.00%-1,365.83%-1,747.55%
2007$1.17M$-3.61M85.35%-308.29%-308.89%
2008$1.19M$-3.79M77.63%-315.04%-318.66%
2009$653134.00$-6.04M34.56%-945.75%-925.08%
2010$262932.00$-5.99M13.03%-802.09%-2,278.89%
2011$125997.00$-1.40M74.52%-307.94%-1,109.55%
2012$66558.00$-1.90M70.88%-2,928.27%-2,853.15%
2013$12160.00$-1.60M20.89%-13,848.68%-13,141.45%
2014$0.00$-27.25M
2015$0.00$-10.86M
2016$0.00$-6.06M
2017$0.00$-4.44M
2018$0.00$-6.83M
2019$0.00$-4.07M
2020$0.00$-3.83M
2021$0.00$-3.55M
2022$0.00$-4.24M
2023$0.00$-4.32M
2024$0.00$333763.00
2025$0.00$30.66M

Frequently asked questions

How much free cash flow does PMCB generate?

PMCB produced $-2.98M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PMCB's balance sheet healthy?

PMCB holds $15.17M in cash and equivalents against — in long-term debt, on $51.89M of shareholder equity. That debt is best read against the cash flow the business throws off each year.